Narrow Ruling in Bilski Is a Win for Dx Developers, Despite Ambiguity on Gene-Patent Questions
June 30, 2010
Narrow Ruling in Bilski Is a Win for Dx Developers, Despite Ambiguity on Gene-Patent Questions
Many in the genetic testing industry have viewed the Bilski decision as a harbinger of the Supreme Court's thinking for future patent cases, including the anti-gene patenting suit filed against Myriad Genetics.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- USPTO Hearing on Confirmatory Gene Testing Raises Calls for Reform Outside Patent System
February 22, 2012 / Pharmacogenomics Reporter - Appeals Court Says Prometheus Meets Machine/Transformation Test; Impact on Gene Patents Uncertain
December 22, 2010 / Pharmacogenomics Reporter - Supreme Court Tasks Lower Court with Determining Criteria for Dx Patentability
June 30, 2010 / Pharmacogenomics Reporter - Game On: Court Ruling on Myriad Patents to Kick off Protracted Legal Battle Over DNA Patentability
March 31, 2010 / Pharmacogenomics Reporter - ACLU, PUBPAT Seek to Challenge Patentability of Isolated Genes Before Supreme Court
October 12, 2011 / Pharmacogenomics Reporter